Local administration of antibiotics for the treatment of respiratory infections has the potential advantage of reduced systemic toxicity and increased drug concentration at the site of infection. This article reviews the basic principles of pulmonary drug delivery using aerosols and the clinical efficacy of local antibiotic therapy of respiratory infections. Clinical studies have been conducted with locally administered aminoglycosides, penicillins, cephalosporins, and polypeptides. The results of these investigations and the pharmacokinetic aspects of pulmonary antibiotic delivery are summarized.
MaxwellDM. The role of antibiotics given by inhalation in chronic chest disease.J Antimicrob Chemother1983; 11: 203–6.
2.
WannerA, RaoA. Clinical indications for and effects of bland, mucolytic and antimicrobial aerosols.Am Rev Respir Dis1980; 122: 79–87.
3.
PenningtonJE. Penetration of antibiotics into respiratory secretions.Rev Infect Dis1981; 3: 67–73.
4.
GoughPA, JordanNS. A review of the therapeutic efficacy of aerosolized and endotracheally instilled antibiotics.Pharmacotherapy1982; 2: 367–77.
5.
StuartBO. Deposition of inhaled aerosols.Arch Intern Med1973; 131: 60–73.
6.
NewmanSP. Aerosol deposition considerations in inhalation therapy.Chest1985; 88(suppl): 1525–605.
7.
StahlhofenW, GebhartJ, HeyderJ. Experimental determination of the regional deposition of aerosol particles in the human respiratory tract.Am Ind Hyg Assoc J1980; 41: 385–98.
8.
NewmanSP, ClarkeSW. Therapeutic aerosols 1-physical and practical considerations.Thorax1983; 38: 881–6.
9.
ClarkeSW, NewmanSP. Differences between pressurized aerosol and stable dust particles.Chest1981; 80(suppl): 907–8.
10.
SwiftDL. Generation and respiratory deposition of therapeutic aerosols.Am Rev Respir Dis1980; 122: 71–7.
OdioW, VanlaerE, KlasterskyJ. Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration.J Clin Pharmacol1975; 15: 518–24.
13.
MarksMI, PrenticeR, SwansonR, CottonEK, EickhoffTC. Carbenicillin and gentamicin pharmacologic studies in patients with cystic fibrosis and Pseudomonas pulmonary infections.J Pediatr1971; 79: 822–8.
14.
KlasterskyJ, GeuningC, MouawadE, DaneauD. Endotracheal gentamicin in bronchial infections in patients with tracheostomy.Chest1972; 61: 117–20.
15.
BaranD, DachyA, KlasterskyJ. Concentration of gentamicin in bronchial secretions of children with cystic fibrosis or tracheostomy.Int J Clin Pharmacol1975; 12: 336–41.
16.
LakeKB, Van DykeJJ, RumsfeldJA. Combined topical pulmonary and systemic gentamicin: the question of safety.Chest1975; 68: 62–4.
17.
HallWH, GerdingDN, SchierlEA. Penetration of tobramycin into infected extravascular fluids and its therapeutic effectiveness.J Infect Dis1977; 135: 957–61.
18.
AlexanderMR, BerglundEM, KasikJE, FoxA, ChinnWM. The concentration of tobramycin in bronchial secretions.Chest1979; 75: 675–9.
19.
StephensD, GareyN, IslesA, LevisonH, GoldR. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis.Pediatr Infect Dis1983; 2: 209–11.
20.
VogelF, KrausgrillP, RommelsheimK, ExnerM, WernerH. Prophylaxe von Pneumonien wahrend der Beatmung durch intratracheale Aminoglykosidapplikation.Umweltmedizin1984; 4: 57–62.
21.
AyresSM, GriesbachJ, GiannelliS. A study of bronchial irritation and systemic absorption of aerosolized kanamycin.Curr Ther Res1972; 14: 153–7.
22.
MayJR, DelvesDM. Treatment of chronic bronchitis with ampicillin.Lancet1965: 1: 929–33.
23.
LambertHP. Clinical significance of tissue penetration of antibiotics in the respiratory tract.Scand J Infect Dis1978; 14: 262–6.
24.
Bergogne-BerezinE, MorelC, BernardY, BerthelotG, KafeH. Pharmacokinetic study of β-lactam antibiotics in bronchial secretions.Scand J Infect Dis1978; 14: 267–72.
25.
WongGA, PeirceTH, GoldsteinE, HoeprichPD. Penetration of antimicrobial agents into bronchial secretions.Am J Med1975; 59: 219–23.
26.
KellyHW, LovatoC. Antibiotic use in cystic fibrosis.Drug Intell Clin Pharm1984; 18: 772–83.
27.
PinesA, RaafatH, PlucinskiK. Gentamicin and colistin in chronic purulent bronchial infections.Br Med J1967; 2: 543–5.
28.
PinesA, RaafatH, SiddigulGM, GreenfieldJSB. Treatment of severe Pseudomonas infections of the bronchi.Br Med J1970; 1: 663–5.
29.
BoxerbaumB, PittmanS, DoershukCF, SternRC, MatthewsLW. Use of gentamicin in children with cystic fibrosis.J Infect Dis1971; 124(suppl): 293–5.
30.
DallyMB, Kurrles, BreslinABX. Ventilatory effects of aerosol gentamicin.Thorax1978; 33: 54–6.
31.
HodsonME, PenkethARL, BattenJC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis.Lancet1981; 2: 1137–9.
32.
KunP, LandauLI, PhelanPD. Nebulized gentamicin in children and adolescents with cystic fibrosis.Aust Paediatr J1984; 20: 43–5.
33.
AndersonCM. Survival in cystic fibrosis.Lancet1984; 2: 292–3.
34.
VogelF, WernerH, ExnerM, MarxM. Prophylaxe und Therapie von Atemwegsinfektionen bei beatmeten Patienten durch intratracheale Aminoglykosidgabe.Dtsch Med Wschr1981; 106: 898–903.
35.
KlasterskyJ, HuysmansE, WeertsD. Endotracheally administered gentamicin for the prevention of infections of the respiratory tract in patients with tracheostomy: a double blind study.Chest1974; 65: 650–64.
36.
KlasterskyJ, HensgensC, NotermanJ. Endotracheal antibiotics for the prevention of tracheobronchial infections in tracheotomized unconscious patients. A comparative study of gentamicin and aminosidin-polymyxin B combination.Chest1975; 68: 302–6.
37.
HoffGE, SchiotzPO, PaulsenJ. Tobramycin treatment of Pseudomonas aeruginosa infections in cystic fibrosis.Scand J Infect Dis1974; 6: 333–7.
38.
FriisB. Chemotherapy of chronic infections with mucoid Pseudomonas aeruginosa in lower airways of patients with cystic fibrosis.Scand J Infect Dis1979; 11: 211–7.
RommelsheimK, KrausgrillP, VogelF, KubnenE, ExnerM. Grundlagen der Pneumonieprophylaxe durch die intratracheale Instillation von Aminoglykosid-Antibiotika.Anasth Intensiv-ther Notfallmed1985; 20: 277–81.
41.
BilodeauM, RoyJC, GirouxM. Studies of absorption of kanamycin by aerosolization.Ann NY Acad Sci1966; 132: 870–8.
42.
LifschitzMI, DenningCR. Safety of kanamycin aerosol.Clin Pharmacol Ther1971; 12: 91–5.
43.
DickieKJ, DegrootWJ. Ventilatory effects of aerosolized kanamycin and polymyxin.Chest1973; 63: 694–7.
44.
BerendtRF, LongGG, WalkerJS. Treatment of respiratory Klebsiella pneumoniae infection in mice with aerosols of kanamycin.Antimicrob Agents Chemother1975; 8: 585–90.
KlasterskyJ, ThysJP, MonbelliG. Comparative studies of intermittent and continuous administration of aminoglycosides in the treatment of broncho-pulmonary infections due to gram-negative bacteria.Rev Infect Dis1981; 3: 74–83.
47.
ScullerJP, CoppensL, KlasterskyJ. Effectiveness of mezlocillin and endotracheally administered sisomicin with or without parenteral sisomicin in the treatment of gram-negative bronchopneumonia.J Antimicrob Chemother1982; 9: 63–8.
48.
BergerVG, GottschalkB, LeupoldW. Erste Erfahrungen mit der Ultra-schall-Aerosolbehandlung unter Heimbedingungen bei Kindern Mit Bronchiektasen.Kinderarztl Prax1978; 10: 523–7.
49.
HuangNN, HillerGJ, MacriCM, CapitanioM, CundyKR. Carbenicillin in patients with cystic fibrosis: clinical pharmacology and therapeutic evaluating.J Pediatr1971; 78: 338–45.
NolanG, McivorP, LevisonH, FlemingPC, CoreyM, GoldR. Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin.J Pediatr1982; 101: 626–30.
52.
GreenfieldS, TeresD, BushnellLS. Prevention of gram-negative bacillary pneumonia using aerosol polymyxin as prophylaxis. I. Effect on colonization pattern of the upper respiratory tract of seriously ill patients.J Clin Invest1973; 52: 2935–40.
53.
KlickJM, DumoulinGC, Hedley-WhyteJ. Prevention of gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis. II. Effect on the incidence of pneumonia in seriously ill patients.J Clin Invest1975; 55: 514–9.
54.
FeeleyTW, DumoulinGC, Hedley-WhyteJ. Aerosol polymyxin and pneumonia in seriously ill patients.N Engl J Med1975; 293: 471–5.
55.
MarschkeG, SarauwA. Danger of polymyxin B inhalation.Ann Intern Med1971; 74: 296–7.
56.
GorskiP, RoznieckiJ, SzmidtM, RychlickaI. Pulmonary function and histaminemia after polymyxin B inhalation.Agents Actions1981; 11: 74–5.
57.
WilsonFE. Acute respiratory failure secondary to polymyxin B inhalation.Chest1981; 79: 237–9.
58.
Valle-JonesJC. A general practice assessment of locabiotal in the treatment of upper respiratory tract infections.J Int Med Res1977; 5: 65–7.
59.
BrodbinP, O'CONNORCA. Fusafungine in the treatment of acute and chronic bronchitis.J Ther1966; 1: 19–21.
60.
NetolitzkyG. Grenzen und neue therapeutische Perspektiven der Microaerolisation von Fusafungin in Fallen von Laryngektomie. Schweiz.Rundsch Med (PRAXIS)1975; 64: 1455–7.
GhaemA, HarpeyC. Evaluation de l'activite anti-inflammatoire de la fusafungine par rhinomanometrie. Etude a double insu contre placebo.JAMA1985; 4(suppl 19): 5–7.
63.
KilburnKH. The innocuousness and possible therapeutic use of aerosol amphotericin B.Am Rev Respir Dis1959; 80: 441–2.
